Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review

British Journal of Cancer

Volumn 94, Issue 11, 2006, Pages 1559-1567

  Bell, R F ^a   Wisloff T ^b   Eccleston, C ^c   Kalso, E ^d  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^c UNIVERSITY OF BATH   (United Kingdom)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cancer pain; Methodology; Opioids; Systematic review

Indexed keywords

HYDROMORPHONE; MORPHINE; OPIATE DERIVATIVE; OXYCODONE; OXYMORPHONE; TRAMADOL;

ANALGESIA; CANCER PAIN; CLINICAL TRIAL; COCHRANE LIBRARY; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; EMBASE; HUMAN; MEDLINE; OUTCOMES RESEARCH; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITATIVE RESEARCH; REVIEW; SUSPENSION; SYSTEMATIC REVIEW; TABLET;

CONTROLLED CLINICAL TRIALS; HUMANS; NEOPLASMS; PAIN; REPRODUCIBILITY OF RESULTS;

EID: 33745251023     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603162     Document Type: Review

References (49)

1. Antczak AA, Tang J, Chalmers DC (1986a) Quality assessment of randomized control trials in dental research. I. Methods. J Periodontal Res 21: 305-314
2. Antczak AA, Tang J, Chalmers DC (1986b) Quality assessment of randomized control trials in dental research. II. Results: periodontal research. J Periodontal Res 21: 315-321
3. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12
4. Jones B, Jarvis P, Lewis J, Ebbutt A (1996) Trials to assess equivalence: the importance of rigorous methods. BMJ 313: 36-39
5. Keefe FJ, Abernethy AP, Campbell LC (2005) Psychological approaches to understanding and treating disease-related pain. Annu Rev Psychol 56: 601-630
6. Landow L (2000) Current issues in clinical trial design: superiority versus equivalency studies. Anesthesiology 92: 1814-1820
7. McCracken LM, Vowles KE, Eccleston C (2004) Acceptance of chronic pain: component analysis and a revised assessment method. Pain 107: 159-166
8. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354: 1896-1900
9. Moore A, Edwards J, Barden J, McQuay H (2003) Bandolier's Little Book of Pain. Oxford: Oxford University Press, p 21
10. Mystakidou K, Tsilika E, Parpa E, Katsouda E, Galanos A, Vlahos L (2005) Assessment of anxiety and depression in advanced cancer patients and their relationship with quality of life. Qual Life Res 14: 1825-1833
11. Smith LA, Oldman AD, McQuay HJ, Moore RA (2000) Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain 86: 119-132
12. Sullivan MJ, Bishop SR, Pivik J (1995) The Pain Catastrophizing Scale: development and validation. Psychol Assessment 7: 524-532
13. Sullivan MJ, Thorn B, Haythornthwaite JA, Keefe F, Martin M, Bradley LA, Lefebvre JC (2001) Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain 17: 52-64
14. Wasan AD, Davar G, Jamison R (2005) The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain 117: 450-461
15. Zaza C, Baine N (2002) Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manage 24: 526-542
16. Boureau F, Saudubray F, d'Arnoux C, Vedrenne J, Esteve M, Roquefeuil B, Siou DK, Brunet R, Ranchere JY, Roussel P, Richard A, Laugner B, Muller A, Donnadieu S (1992) A comparative study of controlled-release morphine (CRM) suspension and CRM tablets in chronic cancer pain. J Pain Symptom Manage 7: 393-399
17. Broomhead A, Kerr R, Tester W, O'Meara P, Maccarrone C, Bowles R, Hodsman P (1997) Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 14: 63-73
18. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16: 3222-3229
19. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, Strasser F, Willey J, Bertolino M, Mathias C, Spruyt O, Fisch MJ (2004) Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 22: 185-192
20. Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M (1996) A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. J Clin Oncol 14: 1713-1717
21. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91: 123-130
22. Cundiff D, McCarthy K, Savarese JJ, Kaiko R, Thomas G, Grandy R, Goldenheim P (1989) Evaluation of a cancer pain model for the testing of long-acting analgesics. The effect of MS Contin in a double-blind, randomized crossover design. Cancer 63: 2355-2359
23. Deschamps M, Band PR, Hislop TG, Rusthoven J, Iscoe N, Warr D (1992) The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine. J Pain Symptom Manage 7: 384-392
24. Finn JW, Walsh TD, MacDonald N, Bruera E, Krebs LU, Shepard KV (1993) Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. J Clin Oncol 11: 967-972
25. Gabrail NY, Dvergsten C, Ahdieh H (2004) Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 20: 911-918
26. Gillette J-F, Ferme C, Moisy N, Mignot L, Schach R, Vignaux J-R, Besner JG, Caille G, Belpomme D (1997) Double-blind crossover clinical and pharmacokinetic comparison of oral morphine syrup and sustained release morphine sulfate capsules in patients with cancer-related pain. Clin Drug Invest 14: 22-27
27. Hagen NA, Babul N (1997) Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 79: 1428-1437
28. Hanks GW, Hanna M, Finlay I, Radstone DJ, Keeble T (1995) Efficacy and pharmacokinetics of a new controlled-release morphine sulfate 200-mg tablet. J Pain Symptom Manage 10: 6-12
29. Hanks GW, Twycross RG, Bliss JM (1987) Controlled release morphine tablets: a double-blind trial in patients with advanced cancer. Anaesthesia 42: 840-844
30. Hays H, Hagen N, Thirlwell M, Dhaliwal H, Babul N, Harsanyi Z, Darke AC (1994) Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 74: 1808-1816
31. Heiskanen T, Kalso E (1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73: 37-45
32. Hoskin PJ, Poulain P, Hanks GW (1989) Controlled-release morphine in cancer pain. Is a loading dose required when the formulation is changed? Anaesthesia 44: 897-901
33. Kalso E, Vainio A (1990) Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 47: 639-646
34. Kaplan R, Parris WC-V, Citron ML, Zhukovsky D, Reder RF, Buckley BJ, Kaiko RF (1998) Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol 16: 3230-3237
35. Klepstad P, Kaasa S, Jystad A, Hval B, Borchgrevink PC (2003) Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain 101: 193-198
36. Knudsen J, Mortensen SM, Eikard B, Henriksen H (1985) Morphine depot tablets compared with conventional morphine tablets in the treatment of cancer pain (Danish). Ugeskr Laeger 147: 780-784
37. Lauretti GR, Oliveira GM, Pereira NL (2003) Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 89: 2027-2030
38. Melzack R, Mount BM, Gordon JM (1979) The Brompton mixture versus morphine solution given orally: effects on pain. Can Med Assoc J 120: 435-438
39. Mignault GG, Latreille J, Viguie F, Richer P, Lemire F, Harsanyi Z, Stewart JH (1995) Control of cancer-related pain with MS Contin: a comparison between 12-hourly and 8-hourly administration. J Pain Symptom Manage 10: 416-422
40. Moriarty M, McDonald CJ, Miller AJ (1999) A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. J Drug Assess 2: 41-48
41. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 2: 239-249
42. O'Brien T, Mortimer PG, McDonald CJ, Miller AJ (1997) A randomized crossover study comparing the efficacy and tolerability of a novel once-daily morphine preparation (MXL capsules) with MST Continus tablets in cancer patients with severe pain. Palliat Med 11: 475-482
43. Parris WC-V, Johnson Jr BW, Croghan MK, Moore MR, Khojasteh A, Reder RF, Kaiko RF, Buckley BJ ( 1998) The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. J Pain Symptom Manage 16: 205-211
44. Portenoy RK, Maldonado M, Fitzmartin R, Kaiko RF, Kanner R (1989) Oral controlled-release morphine sulfate. Analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients. Cancer 63: 2284-2288
45. Stambaugh JE, Reder RF, Stambaugh MD, Stambaugh H, Davis M (2001) Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 41: 500-506
46. Thirlwell MP, Sloan PA, Maroun JA, Boos GJ, Besner JG, Stewart JH, Mount BM (1989) Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 63: 2275-2283
47. Walsh TD (1985) Clinical evaluation of slow-release morphine tablets. In Advances in Pain Research and Therapy, Fields HL et al (eds) pp 727-731. New York: Raven Press
48. Walsh TD, MacDonald N, Bruera E, Shepard KV, Michaud M, Zanes R (1992) A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. Am J Clin Oncol 15: 268-272
49. Wilder-Smith CH, Schimke J, Osterwalder B, Senn H-J (1994) Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 5: 141-146